Some 20 years ago the introduction of levodopa opened a new era in the treatment of Parkinson's disease. Although levodopa remains the single most effective drug for the treatment of this maladie, challeng ing therapeutic problems arise in many patients after several years of sustained treatment. Among these, fluctuations in motor performance and drug-induced involuntary movements are the most troublesome. The search for improved antiparkinsonian medications therefore con tinues and important new developments have already occurred, for example the introduction of the dopaminergic ergots and the selective MAO-B-inhibitor selegeline (deprenyl) into routine treatment. The International Workshop on Parkinson's Disease held in Inns bruckjIgls primarily considered a new compound with antiparkinsonian properties unrelated to any of the conventional drugs - the diphenyl ex piperidine compound budipine. The present volume records the perimental and clinical data on budipine presented at the meeting. The editors felt especially encouraged by the authorative biochemical, physiological, clinical and therapeutic reviews that were given at this symposium by outstanding experts in the field of extrapyramidal dis orders. Their inclusion should make this volume a valuable source of information on a variety of current research aspects into Parkinson's disease. InnsbruckjLondon, October 1984 The Editors v Contents James Parkinson and the Treatment of His Disease. G. Stern ....

James Parkinson and the Treatment of His Disease

Biochemical Neuropathology: A New Approach to Parkinson's Disease
Clinical Neurophysiology of Parkinson's Disease
Dopaminergic Agonists and Receptors: Their Relevance to the Treatment of Parkinson's Disease
Brain Dopaminergic Receptor Changes in Parkinson's Disease in Relation to the Disease Process and Treatment
Analysis of Akinesia
Observations of Voluntarily Induced Automatic Motor Behaviour in Parkinsonism
Significance of Mental Disorders in the Long-Term Treatment of Parkinson's Disease
Treatment of Parkinson's Disease in Early and Late Phases
Relevance of Dopaminergic Agonists and Antagonists to Parkinsonian Tremor
Therapeutic Possibilities in On-Off Phenomena in Parkinson's Disease
Target and Additive Drugs in the Treatment of Parkinson's Disease: A Pilot Study
Pharmacologic Bases of Antiparkinsonian Therapy
The Pharmacodynamics of Budipine on Central Neurotransmitter Systems
Biochemical and Pharmacologic Aspects of the Mechanism of Action of Budipine
Pharmacokinetics and Metabolism of Budipine in Animals and Humans
Clinical Experience with Budipine in Parkinsonian Therapy
Controlled Single-Blind Trial of Budipine. L-Dopa, and Amantadine in 102 Patients with Parkinson's Disease
Open Clinical Trial of Budipine in 25 Tremor-Dominant Parkinsonian Patients
Effect of Budipine on Parkinsonian Tremor Resistant to Other Antiparkinsonian Medication
Budipine: A New Chemical Substance in the Treatment of Parkinson's Disease
Observations on the Therapeutic Effect of Budipine on Parkinson's Disease
Long-Term Treatment with Budipine
Budipine Treatment of Neuroleptic-Induced Parkinsonism
Randomized Double-Blind Trial of Budipine and Biperiden in Patients withNeuroleptic Extrapyramidal Symptoms
The Effect of Budipine on the Rheology of the Blood
EMG and Computer Analysis of Patients with Tremor and Rigidity Under Budipine Therapy
Vigilance Study Using Electrooculographic and Electroencephalographic Methods After Acute Budipine Administration in Healthy Subjects
Budipine in the Treatment of Extrapyramidal Disorders Not Related to Parkinson's Disease.